Clinical trial · Interventional
Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.
NCT06971965CI-TRIAL-00089677MAeSTro-TSHnot yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Carcinoma | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Levothyroxin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- low TSH group
- description
- 0.3 ≤ target TSH \<2.0mIU/L
- interventionNames
- Drug: Levothyroxin
- type
- EXPERIMENTAL
- label
- high TSH group
- description
- 2.0 ≤ target TSH \<8.0mIU/L
- interventionNames
- Drug: Levothyroxin
Primary outcomes (1)
- measure
- Rate of Disease progression
- timeFrame
- at 3,5years after enrollment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation. * Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype). * Non-pregnant women of childbearing potential (confirmed by medical history taking) Exclusion Criteria: * Hyperthyroidism * If the investigator determines that you are not suitable for clinical research participation considering the following comorbidities: * Myocardial infarction or cerebrovascular accident within the last three months. * Diseases with limited life expectancy or potentially impairing the patient's ability to comply with at least five years of treatment or follow-up.
References
Publications (0)
Data not yet available
No reference posted for this study.